OXURION NV to Present at Wet AMD and DME Drug Development Summit
13 Aprile 2021 - 07:30AM
OXURION NV to Present at Wet AMD and DME Drug Development Summit
Leuven, BE, Boston, MA, US – April 13th,
2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR),
a biopharmaceutical company developing next generation
standard-of-care ophthalmic therapies, with a clinical stage
portfolio in retinal vascular disorders, today announces that Grace
Chang, M.D., Ph.D., Chief Medical Officer (CMO) of Oxurion, will be
presenting at the Wet AMD and DME Drug Development
Summit, taking place from April 13 to 15, 2021.
Dr. Chang will be joining the Summit as a
presenter and a panelist:
• Presentation on New Therapeutics Target RGD
Integrins and The Plasma Kallikrein System: Overview of First
Clinical FindingsDate & Time: April 15, 2021 at 9:55 am
EDT • Participation
in Q&A session entitled Targeting New Therapeutic Pathways
& Looking Beyond Anti-VEGFDate & Time: April 15, 2021 at
10:35 am EDT
•
Participation in Panel Discussion on the Topic Searching for
Novel Therapeutic Targets – Addressing Developmental Challenges for
New Drug Candidates in Wet AMD & DMEDate & Time: April 15,
2021 at 11:10 am EDT
For more information and registration
details: https://wet-amd-drugdevelopment.com
Under the leadership of Dr. Chang, Oxurion is
advancing a pipeline of innovative clinical drug candidates with
distinct and complementary modes of action, for treatment of
retinal vascular disorders, including DME but also wet AMD.
THR-149 is a potential first in class plasma
kallikrein inhibitor with the possibility to become the treatment
of choice for the 40% DME patients who respond sub-optimally to
anti-VEGF therapy. Oxurion is currently recruiting patients in a
Phase 2 and is on track to readout Part A data later this
year.
THR-687 is a potential best in class small
molecule pan-RGD integrin antagonist initially being developed to
treat DME with the possibility to become the standard of care for
most DME patients. The Company is currently preparing an IND to
start a Phase 2 study evaluating THR-687 as a new therapy for most
DME patients. This Phase 2 is expected to start in mid-year.
Beyond DME, THR-687 also has development
possibilities in additional retinal vascular disorders including
for wet age-related macular degeneration (Wet AMD) and retinal vein
occlusion (RVO), thereby potentially allowing the Company to tap
into a broader therapeutic market with a current combined estimated
annual value of $12 billion.
END
For further information please contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 478 33 56
32wouter.piepers@oxurion.com |
EU Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer
HallTel: +44 20 7638 9571oxurion@citigatedewerogerson.com
USWestwicke, an ICR CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (AMD) and retinal vein
occlusion (RVO).
Oxurion is aiming to build the leading global
franchise in the treatment of retinal vascular disorders based on
the successful development of its two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor being developed as a
potential new standard of care for the 40% of DME patients who
respond sub-optimally to anti-VEGF therapy. THR-149 has shown
positive topline Phase 1 results for the treatment of DME. The
Company is currently conducting a Phase 2 clinical trial evaluating
multiple injections of THR-149 in DME patients who previously
responded sub-optimally to anti-VEGF therapy. THR-149 was developed
in conjunction with Bicycle Therapeutics PLC (NASDAQ:
BCYC).
- THR-687 is a pan-RGD integrin antagonist that is initially
being developed as a potential first line therapy for DME patients.
Positive topline results in a Phase 1 clinical study assessing
THR-687 as a treatment for DME were announced in 2020. THR-687 is
expected to enter a Phase 2 clinical trial in mid-2021. THR-687,
also has the potential to deliver improved treatment outcomes for
patients with wet AMD and RVO. THR-487 is an optimized compound
derived from a broader library of integrin antagonists in-licensed
from Galapagos NV (Euronext & NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and
is listed on the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2023 a Mar 2024